European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT Newswires00:04

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Simply Wall StDec 24, 2024 20:41

Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $220

Futu NewsDec 21, 2024 02:31 · Ratings

Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults

BenzingaDec 19, 2024 21:42

Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $194

Futu NewsDec 18, 2024 23:31 · Ratings

A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $167 to $211

Futu NewsDec 17, 2024 21:00 · Ratings